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AbstrACt
Introduction In the USA, Food and Drug Administration 
regulations prohibit the sale of flavoured cigarettes, 
with menthol being the exception. However, the 
manufacture, advertisement and sale of flavoured cigar 
products are permitted. Such flavourings influence 
positive perceptions of tobacco products and are linked 
to increased use. Flavourings may mask the taste of 
tobacco and enhance smoke inhalation, influencing 
toxicant exposure and abuse liability among novice 
tobacco users. Using clinical laboratory methods, this 
study investigates how flavour availability affects 
measures of abuse liability in young adult cigarette 
smokers. The specific aims are to evaluate the effect of 
cigar flavours on nicotine exposure, and behavioural and 
subjective measures of abuse liability.
Methods and analyses Participants (projected n=25) are 
healthy smokers of five or more cigarettes per day over the 
past 3 months, 18–25 years old, naive to cigar use (lifetime 
use of 50 or fewer cigar products and no more than 10 
cigars smoked in the past 30 days) and without a desire 
to quit cigarette smoking in the next 30 days. Participants 
complete five laboratory sessions in a Latin square 
design with either their own brand cigarette or a session-
specific Black & Mild cigar differing in flavour (apple, 
cream, original and wine). Participants are single-blinded 
to cigar flavours. Each session consists of two 10-puff 
smoking bouts (30 s interpuff interval) separated by 1 hour. 
Primary outcomes include saliva nicotine concentration, 
behavioural economic task performance and response to 
various questionnaire items assessing subjective effects 
predictive of abuse liability. Differences in outcomes 
across own brand cigarette and flavoured cigar conditions 
will be tested using linear mixed models.
Ethics and dissemination The Virginia Commonwealth 
University Institutional Review Board approved the study 
(VCU IRB: HM20007848). Dissemination channels for study 
findings include scientific journals, scientific meetings, and 
policy briefs.
trial registration number NCT02937051.
IntroduCtIon 
In 2009, the US Food and Drug Administra-
tion (FDA) banned cigarettes with character-
ising flavours (except for menthol1), given 
their appeal to youth.2 Five years later, the 
FDA proposed broader regulatory authority 
over cigars but did not restrict the availability 
of flavoured cigars.3 However, in March 2018, 
an Advanced Notice of Proposed Rulemaking 
was issued by the FDA, in which commentary 
and research are sought to inform the regula-
tion of flavours in tobacco products including 
cigars.4 These ongoing changes in tobacco 
regulation and the evolution of the tobacco 
marketplace highlight the need for empir-
ical evidence regarding the use and appeal of 
cigar products and their associated flavours.
The availability of flavours for cigars, among 
other product characteristics, has been linked 
to increased cigar sales5 and consumption.6 
These increases are greatest among youth/
strengths and limitations of this study
 ► This study will provide the opportunity to examine 
the abuse liability across flavours of one of the 
most popular cigar brands in a population that is 
at increased risk of harm from flavoured tobacco 
products.
 ► The study triangulates abuse liability assessment 
in a clinical laboratory setting using physiological, 
behavioural and subjective measures.
 ► Use of behavioural economic tasks to measure 
abuse liability for cigars represents a novel ap-
proach to understand this tobacco product type.
 ► As this study is being conducted in a controlled set-
ting at a single site, results may not generalise to 
other use conditions/settings or among other popu-
lations/geographic regions.
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young adults.2 7 8 In 2012–2013, 7.3% of US adults smoked 
cigars every day or some days,9 and 12.6% of high school 
students reported past month use.10 The vast majority 
(nearly 90%) of youth/young adult cigar smokers report 
usual brands that offer flavoured varieties.2 Black & Mild 
(B&M) is the most popular brand among cigar smokers, 
offering at least eight flavoured varieties11 and, accord-
ingly, a much greater proportion of 12–17-year-old cigar 
users (51%) prefer B&M compared with those 35 or 
older (18%).2 The range of flavoured cigars is vast and 
includes flavours that are fruit-like (Apple, Peach), food/
dessert-like (Cream, Dulce de Leche), alcohol-like (Wine, 
Double Barrel Rum) and unlike anything normally 
associated with gustatory or olfactory sensation (Jazz, 
Diamonds)11 12; fruit, sweet/candy and wine are the most 
popular flavours.2 13 14 Evidence from tobacco industry 
documents and epidemiological work suggests that such 
flavour additives are used to promote appeal among 
novice users15–17 as well as to mask the taste of tobacco 
and enhance smoke inhalation.18 Additionally, a strong 
literature supports the role of flavours in influencing posi-
tive perceptions, and ultimately use, of tobacco products 
including cigars.2 19–22 Flavoured cigar use among youth 
is also associated with lower intentions to quit compared 
with youth who use non-flavoured tobacco products.23 In 
tandem with cigar flavours, factors like marketing and 
price may promote initiation and continued use.7 17 24 
For example, B&Ms are defined by weight (more than 
3 lbs/1000) in the USA as large cigars via tax guide-
lines11 and thus are much cheaper than some other cigar 
subtypes. Together, these factors combine to make cigars 
appealing, suggesting the need to better understand the 
extent to which flavours influence the potential for initia-
tion and subsequent use of cigars.
Clinical laboratory methods provide an important means 
to understand how flavour may influence tobacco product 
use patterns and abuse liability. Generally, abuse liability 
is the degree to which a psychoactive drug or formulation 
would be used for non-medical purposes and abuse of 
that drug would lead to physical or psychological depen-
dence.25 With respect to tobacco products, abuse liability 
refers to the likelihood that a given product’s reinforce-
ment value will lead to persistent use and dependence.26 
The clinical laboratory setting allows for systematic, effi-
cient assessment of physiological effects (eg, nicotine and 
toxicant exposure, cardiovascular response), behavioural 
choice tasks and subjective responses,27 all of which are 
important for predicting tobacco use patterns including 
the likelihood for progression to regular use, potential 
for harm28 and abuse liability.24–26 For example, among 
regular B&M cigar smokers, completing two 10-puff bouts 
of an active (lit) B&M yielded significantly greater nico-
tine exposure, heart rate, expired air carbon monoxide 
(CO) and positive subjective effects compared with two 
10-puff bouts of an unlit B&M (sham).29 However, relative 
to combustible tobacco cigarettes (CTCs), B&M cigars 
appear to deliver less nicotine per puff and produce 
higher CO exposure and greater smoke volume in both 
primarily CTC and primarily cigar smokers.29–32 In terms 
of subjective measures, B&Ms may produce acute posi-
tive subjective effects (ie, increased ratings of ‘satisfying,’ 
‘calm you down’) as well as those indicative of drug effects 
(increased ratings of ‘dizzy’),29 30 but the only existing 
direct comparison of subjective effects between cigarettes 
and cigars (performed among dual users of cigarettes 
and cigars) suggests that cigarettes are more effective 
at reducing the craving to smoke.33 Behavioural choice 
tasks such as the cigarette purchase task and multiple 
choice procedure assess abuse liability by measuring how 
hypothetical or potentially real consumption of tobacco 
products changes in response to the price of these prod-
ucts,34–38 providing evidence on how reinforcing these 
products are. These behavioural choice tasks have not 
been used to assess cigars and, importantly, no studies 
have controlled for the influence of cigar flavour on any 
of the above outcomes in the clinical laboratory. Flavours 
could affect cigar appeal among novice users,15–17 and 
increase cigar smoke inhalation,18 leading to increased 
nicotine exposure and subsequent continued use. As 
previous work from our team39 and others40 41 supports, 
simultaneously assessing physiological, behavioural and 
subjective measures in the clinical laboratory allows effi-
cient and cost-effective testing of all of these hypotheses.
Considering the current tobacco marketplace and 
increasing rates of cigar use among vulnerable popu-
lations,2 7 8 evaluating the effects of cigar flavours on 
abuse liability is essential to protecting public health 
and informing FDA regulation of cigars. Clinical labora-
tory methods are uniquely suited to measure the effects 
of cigar flavours on abuse liability by using a controlled 
setting to provide much-needed data. Our research uses 
an innovative approach and includes key advances to 
improve our understanding of how cigar flavours may 
influence use. These innovations include: (1) testing 
the most popular cigar brand and flavours, (2) triangu-
lating abuse liability in the laboratory using physiological, 
behavioural and subjective measures and (3) purposeful 
accrual of a population at increased risk of harm from 
flavoured cigar products (ie, young adult cigarette 
smokers). The specific aims of the study are to evaluate 
the effect of cigar flavours on (1) nicotine exposure, (2) 
behavioural measures of abuse liability and (3) subjective 
measures of abuse liability.
MEthods And AnAlysEs
Patient and public involvement
Neither patients nor the public were involved in the formu-
lation of research questions, outcome measures, experi-
mental design, recruitment or conduct of the study. Results 
from the study, as well as additional information about the 
study, will be provided to participants on request.
study design
This study involves 25 current young adult cigarette 
smokers who complete five Latin square ordered, 
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within-subject laboratory conditions that differ by the 
tobacco product used: (1) own brand cigarette (positive 
control), (2) original-flavoured B&M cigar, (3) apple-fla-
voured B&M cigar, (4) cream-flavoured B&M cigar and 
(5) wine-flavoured B&M cigar. The study takes place in 
a clinical laboratory setting at Virginia Commonwealth 
University (VCU). VCU is a diverse, urban campus located 
in Richmond, Virginia, USA.
study population
The study population is young adult (18–25 years old) 
cigarette smokers from the greater Richmond area who 
report little to no experience with cigars, cigarillos or 
little cigars (naive; smoked no more than 50 cigar prod-
ucts of any type in lifetime with no more than 10 cigars 
in the past 30 days) and who are not planning to quit 
smoking cigarettes in the next 30 days.
Inclusion criteria
To be included, participants must be healthy, as deter-
mined by self-report and by measured heart rate/blood 
pressure (HR/BP), ages 18–25 and willing to provide 
informed consent. They must agree to attend laboratory 
sessions and abstain from tobacco/nicotine as required, 
to use the designated products and to follow the study 
protocol. Participants are regular cigarette smokers 
(≥5 cigarettes/day for the past 3 months) naive to cigar 
products, who provide a semiquantitative urine cotinine 
result of ≥3 (100–200 ng/mL) at screening (NicAlert test; 
Jant Pharmacal Corporation, Encino, Los Angeles, Cali-
fornia, USA).
Exclusion criteria
Individuals with a self-reported history of chronic diseases 
or psychiatric conditions are excluded. A chronic disease 
in this study is defined as any chronic medical condition 
that an individual has had for 3 or more months. Other 
exclusion criteria are: history of or active cardiovascular 
disease, current oral health problems or injuries, low/
high BP (self-reported or confirmed during screening), 
seizures or other medical conditions/allergies that may 
interact with study conditions. Use of regular prescrip-
tion medication (other than vitamins or birth control) 
and past-month use of cocaine, opioids, benzodiazepines 
and methamphetamine (self-report) are exclusionary. 
Individuals who report using cannabis or alcohol on >20 
of the past 30 days also are excluded. Women who report 
breastfeeding or test positive for pregnancy (by urinal-
ysis) at screening are excluded.
Withdrawal criteria
If a participant fails to comply with the study protocol 
prior to or during one session, they are offered the oppor-
tunity to repeat the condition once. Failure to comply a 
second time is ground for withdrawal by the principal 
investigator (PI). Additionally, participants who experi-
ence adverse health effects are considered for withdrawal 
following consultation with the study’s medical monitor. 
Possible adverse health effects include any side effect, 
injury, sensitivity reaction or any other illness or condi-
tion occurring while a participant is in the study. Partici-
pants are also permitted to self-withdraw from the study 
at any point. If they chose to remove themselves from the 
study, they will receive no future contact from the study 
site. All participants who are withdrawn at any point, for 
any reason, will be replaced until a total of 25 participants 
have completed the study.
recruitment and enrolment
Interested individuals identify themselves by responding 
to institutional review board (IRB)-approved advertise-
ments for cigarette smoking research studies. Participants 
are recruited via in-person recruitment, websites, message 
boards, print advertisements, web-based advertisements 
(eg,  craigslist. org) and approved tobacco study regis-
tries. Participants begin by completing a survey, either by 
phone or online, to assess eligibility. Participants also are 
provided the opportunity to consent to joining a registry, 
and, should they consent, any answers that are provided 
are maintained for future contact purposes. If a partici-
pant is deemed potentially eligible, they are invited into 
the laboratory to undergo an in-person screening visit 
that includes administration of informed consent proce-
dures and assessment of additional eligibility criteria. The 
study is explained fully to the potential participant, and, 
after being provided adequate time to read the informa-
tion and ask questions, participants are asked to sign and 
date the informed consent document.
Following consent, participant eligibility is confirmed 
via a baseline questionnaire. Participants are also asked to 
provide a urine sample, which is used to test for cotinine 
levels to verify smoking status and, for women, to test for 
pregnancy. Additional physiological data are collected 
from participants for eligibility and baseline assessment 
purposes (ie, height, weight, baseline BP, baseline HR and 
expired breath CO levels). Following review of all base-
line information, eligible participants are then enrolled 
into the study.
Condition assignment and materials
After enrolment, eligible participants are assigned a 
condition order and scheduled for the first of five sessions. 
Participants attend one session for each of the five condi-
tions, each occurring at least 48 hours apart. Condition 
orders are counterbalanced using a Latin square to 
help control for carryover effects. The Latin square was 
created in advance, reviewed by the study statistician for 
accuracy and is stored in a secure, password-protected 
database that is only accessible to study staff. The study 
staff are unblinded to condition orders and prepare the 
appropriate session product prior to each session. Partici-
pants are blind to the flavour assignment for B&M condi-
tions. The own brand cigarette session is not blinded, as 
the product visibly differs from cigars.
Four flavours of plastic-tipped B&M cigars (John 
Middleton, Altria; Richmond, Virginia, USA)—stored 
in a dark, dry, temperate location in order to minimise 
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the possibility of staleness or mould—are used: ‘Apple’, 
‘Cream’, ‘Wine’ and ‘Original’. The fifth condition, own 
brand cigarette, functions as a positive control. Self-re-
ported own brand cigarettes are purchased locally by 
the study staff following enrolment and are stored in a 
separate container in the same location as the cigars.
Compensation
Participants are compensated for their time and incon-
venience at the end of each session and study compen-
sation is delivered in increasing amounts across sessions 
to encourage retention. Participants who complete the 
entire study are paid $360 in total (session 1=$50; 2=$60; 
3=$70; 4=$80; 5=$100). Participants are provided the 
opportunity to receive up to an additional $10.24 during 
each session depending on choices made and randomly 
chosen for reinforcement during completion of the 
behavioural measures.
Measurement instruments
Baseline questionnaire
The baseline survey is a computer-based self-assessment 
that includes items regarding demographic characteris-
tics, health history, tobacco use, alcohol use, drug use, 
tobacco product harm perceptions, nicotine depen-
dence and time preferences. Demographic charac-
teristics include race/ethnicity, age and employment 
status. Health history includes yes/no items assessing 
history of or active cardiovascular disease, low/high BP, 
seizures, depression, anxiety and other physical health/
psychiatric conditions as well as regular prescription 
medication use. Tobacco use items include ever use and 
past month use of cigarettes, cigars, hookah, smokeless 
tobacco and electronic cigarettes as well as more detailed 
measures regarding cigarette smoking behaviour/history 
and number of cigar products used in lifetime. Tobacco 
product harm perception items were adapted from stan-
dardised national surveys.42 43 Nicotine dependence was 
assessed using the Fagerstrom Test for Nicotine Depen-
dence.44 Four questions that followed a similar format, 
‘Would you rather win/lose $20 now or $30 a year from 
now?’, were asked to assess time preference.45
Biological and physiological measures
Before and after each smoking bout (for a total of four 
times per session), participants provide saliva samples 
using methods and procedures consistent with Salimetrics 
‘Passive Drool with Saliva Collection Aid’.46 Saliva samples 
are frozen immediately (−80°C) following collection for 
later analysis, conducted by a partner laboratory using 
previously developed assays.47 Saliva and plasma nicotine 
levels have been found to be highly correlated in an exam-
ination of exposure via the nicotine patch (r=0.82),48 and 
saliva nicotine has been used in acute exposure CTC 
paradigms among adolescents with greater exposure 
noted among more dependent smokers.49 Further, saliva 
assays of nicotine are less invasive and potentially more 
sensitive than plasma, as saliva nicotine concentrations 
are higher relative to plasma.48 50 Secondary physiological 
measures include expired air CO concentration, as well 
as HR and BP. Expired air CO is assessed via a BreathCO 
monitor (Vitalograph, Lenaxa, Kansas, USA). HR/BP 
is measured and saved electronically using software and 
equipment that also sounds an alarm if safety parameters 
are exceeded (Model 506, Criticare Systems).
Behavioural measures
Three behavioural choice tasks (cigarette/cigar purchase 
task, cross product purchase task and multiple choice 
procedure) are administered at the completion of each 
session to assess abuse liability. The cigarette/cigar 
purchase task (adapted from Jacobs and Bickel34) is a 
hypothetical purchase task wherein participants are asked 
how many times they would take 10 puffs of the session 
product (cigar or cigarette depending on condition assign-
ment) if they were offered at each of 16 different prices 
($0.00, $0.01, $0,02, $0.04, $0.08, $0.16, $0.32, $0.64, 
$1.28, $2.56, $3.84, $5.12, $6.40, $7.68, $8.96, $10.24). 
This measure has been shown to approximate actual 
consumption of addictive substances.51 The cigarette and 
cigar purchase tasks produce five outcome measures: 
breakpoint, the price at which participants switch from 
choosing the tobacco product to choosing money; elas-
ticity (price sensitivity), a measure of how hypothetical 
consumption changes in response to changes in price; 
intensity, hypothetical consumption at $0 (free); Omax, 
the maximum hypothetical expenditure across prices (ie, 
the maximum of the product of reported consumption 
and price); and Pmax, the price corresponding to Omax. 
Breakpoint, intensity, Omax and Pmax will be derived 
directly from the data,35 while elasticity will be calculated 
using the following equation from Koffarnus et al.52:
  Q = Qo × 10k(e
−αQoC−1)
  
In the equation above, Q is consumption at a given 
price, Q0 is consumption at $0 (also known as intensity), α 
is elasticity, C is price and k is a constant representing the 
span of the data in log10 units. The value of k is typically 
set equal to the log10 of the highest reported consump-
tion value minus log10 of the lowest reported consump-
tion value, so we will determine the appropriate k value 
once data are collected, but we will also consider other 
values of k that provide the best fit for the data as deter-
mined by goodness of fit (R2 values) for demand curves.
Cigarette/cigar purchase task data for each partic-
ipant will be assessed for usability using two of Stein et 
al.’s three criteria for non-systematic data identification.53 
The two criteria are trend, or whether consumption gener-
ally decreases as price increases, and bounce, or whether 
there are multiple instances of increases in consumption 
between consecutive prices and this jump in consump-
tion exceeds 25% of the original consumption at $0. 
Stein et al.’s third criterion, reversals from zero—which 
suggests discarding data when any non-zero consump-
tion is reported after two reports of zero consumption 
at consecutively increasing prices—will not be used. 
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This difference is because our computer-based purchase 
task ends the task after two consecutive reports of zero 
consumption, so reversals from zero will not be observed. 
Data not meeting these criteria will be discarded from 
cigarette/cigar purchase task analyses.
The cross-product purchase task is a similar hypothet-
ical purchase task that asks participants how many times 
they would purchase 10 puffs from their own brand ciga-
rette at various prices in the same range as described 
above when 10 puffs of the session-specific cigar is also 
available at a constant price ($1.00); this task is admin-
istered only during the four cigar conditions. The cross-
product purchase task produces cross-price elasticity,54 55 
defined for each participant as the slope from a regres-
sion of log-consumption of cigars (at the fixed price of 
$1) on log-cigarette price. A positive value for this slope 
would suggest that the flavoured cigar is (at least partially) 
substitutable for own brand cigarettes.
The multiple choice procedure involves participants 
making choices between tobacco products and various 
amounts of money.38 In the current study, this task shows 
three columns consisting of 15 different choices: the first 
column assigns a choice number to each of the choices, 
the second column provides the option of 10 puffs of 
the session product and the third offers various amounts 
of money in amounts that increase as choice number 
increases ($0.01–$10.24; identical to the cigarette/
cigar purchase task except for the lack of $0.00 option). 
The participant makes 15 different decisions between 
10 puffs of the session product and various amounts of 
money. Once the decisions are made, one of these 15 
decisions is selected via a random draw of a ball from 
an opaque bag; each ball is numbered 1–15 to reflect 
one of the numbered choices in the task. If the result of 
the randomly selected choice is 10 puffs of the session 
product, the participant is given a 10 min consumption 
period in which to smoke 10 puffs of the session product 
(ad lib), after which the participant undergoes an addi-
tional 10 min rest period prior to the end of the session. 
If the randomly selected choice is one of the amounts 
of money, the participant is given that amount of money 
immediately, followed by a 10 min ‘consumption’ period 
and a 10 min rest period. The multiple choice procedure 
produces the crossover point, measured in US dollars, 
which represents the highest price at which participants 
chose the tobacco product instead of the money.39 56 57 
Data will be excluded for those participants with incon-
sistent choices (ie, those who switch back from choosing 
money to choosing tobacco products at higher prices).
A secondary behavioural measure of smoking 
behaviour (puff topography) is collected during the two 
smoking bouts (10 directed puffs per bout, 30 s interpuff 
interval) per session using the eTop topography instru-
ment developed and manufactured at the American 
University of Beirut (AUB). The AUB research group has 
a record of topography instrumentation development 
for alternative tobacco products.58 Similar to commer-
cially available cigarette topography instruments, the 
instrument senses flow-induced pressure drop across an 
orifice incorporated into the mouthpiece. The pressure 
drop is sensed by a pressure transducer whose output 
voltage every 100 milliseconds is amplified, digitised 
and sampled. Specific topography measures of interest 
include puff duration, average puff volume, flow rate 
and total puff volume inhaled. Mouth pieces for cigars 
and cigarettes are individually calibrated prior to each 
session to relate puff velocity (mL/s) to the pressure 
transducer voltage signal.59 60
Subjective measures
Subjective measures are assessed at nine points during 
each session. Subjective measures consist of the short-
form of the Addiction Research Centre Inventory 
consisting of 49 true–false items,61 the general Labelled 
Magnitude Scale for rating flavour intensity,62 the Direct 
Effect Scale63 and the Direct Effects of Tobacco Scale.64 65 
An additional 12 items are designed to assess tobacco 
abstinence symptoms and more general drug effects and 
include items like ‘Urges to smoke a cigarette’ and ‘Do 
you feel a rush?’. Each of these measures has been used 
previously to assess the subjective effects of a variety of 
drugs and tobacco products.66–68
Primary outcomes
The primary outcomes of this study include physiological, 
behavioural and subjective measures. The primary physi-
ological outcome is saliva nicotine. Primary outcomes for 
behavioural measures of abuse liability are breakpoint, elas-
ticity, intensity, Omax and Pmax from the cigarette/cigar 
purchase task, cross-price elasticity from the cross-product 
purchase task and crossover point from the multiple choice 
procedure. Subjective measures predictive of abuse liability, 
reinforcing effects and acceptability-related items are used 
as the primary subjective outcomes.
Secondary outcomes
The secondary outcome measure is puff topography, 
a behavioural measure of smoke inhalation that can be 
indicative of toxicant exposure.69 Puff topography data 
will be collected during both bouts in each session and 
includes puff duration, average puff volume, flow rate 
and total puff volume inhaled.
session timeline
Prior to each session, participants are instructed to 
abstain from nicotine/tobacco for at least 12 hours. Absti-
nence is verified by measuring expired air CO levels at the 
beginning of each session. Participants with an expired 
air CO reading >10 ppm are considered non-compliant 
with abstinence requirements, rescheduled if applicable 
and provided an opportunity to comply with session 
protocol on another day. Once compliance with the absti-
nence period is verified, physiological data collection 
will begin and participants are instructed to rinse their 
mouth with water to remove any food residue and begin a 
30 min rest period in order to achieve resting HR and BP 
(figure 1). Following the rest period, participants provide 
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a saliva sample, expired air CO is measured and subjec-
tive measures are completed.
Product administration begins following completion 
of baseline subjective measures. Product administration 
consists of 10 directed puffs with a 30 s interpuff interval 
and is monitored and recorded using a puff topography 
system. There are two product administrations during 
each session, with the second occurring 60 min after 
the first. The participant completes subjective measures 
at 5, 15, 30 and 45 min following each product adminis-
tration (including baseline, nine times in total). Saliva is 
collected 10 min after each product administration and 
5 min before the second product administration (four 
saliva samples per session). To assess CO boost, expired 
air CO concentration is assessed at baseline, 15 min 
after each product administration and 5 min before the 
second product administration (four CO assessments 
each session). HR/BP are recorded throughout the 
entire session. Following both product administrations 
and completion of all subjective measures, behavioural 
task measures are assessed by completion of either one 
or two hypothetical purchase tasks (cigarette purchase 
task during the own brand cigarette condition; cigar 
purchase task and cross-product purchase task during 
cigar conditions) as well as the multiple choice proce-
dure for cigarettes in the own brand condition and for 
the session-specific cigar in the cigar conditions.
data monitoring, sample requirements and statistical 
analyses
Data and safety monitoring
All baseline questionnaire and subjective response data 
are collected at the study site and entered electronically 
through the Research Electronic Data Capture system 
(REDCap70), a secure database system, hosted at VCU, 
and resemble paper forms that received the approval 
of the study site IRB. Data quality of participant-entered 
forms are monitored by site personnel during all sessions 
for completeness, validity and integrity. In the cases where 
study personnel observe incomplete or inconsistent 
responses, study personnel verify responses with partici-
pants and update the electronic record if needed. Data 
entered by personnel are checked for accuracy by other 
site personnel and detailed item inquiries are recorded 
and tracked. Review and modifications are made as 
needed, and any information regarding such modifi-
cations are recorded and associated with a study staff 
member based on REDCap user name. Ability to make 
such modifications is restricted based on an individual 
personnel’s position and privileges. A response to each 
inquiry is needed for the queried item to be considered 
closed. Data will be monitored for quality purposes every 
6 months by the PI and coinvestigator.
While adverse events (AEs; ie, incidents of high BP) 
and serious AEs (SAEs; ie, any AE that requires hospital-
isation) are not expected, as this protocol is considered 
low risk, all research staff who interact with participants 
are instructed on procedures involved in managing and 
reporting any potential AEs and SAEs. Any AEs or SAEs 
are well documented, and these records will be main-
tained for regular review by the study staff. AEs and SAEs 
are monitored during sessions by study staff and assessed 
by the researcher for severity and expectedness/related-
ness to the study. All documented AEs are reviewed by 
the PI and coinvestigator within 1 week of occurrence; 
SAE documentation is reviewed within 24 hours. Further, 
in the case of an SAE, the medical monitor also is noti-
fied and consulted. All AEs are reported to the study site 
IRB as part of an annual report, while all SAEs that are 
unexpected and deemed related or possibly related are 
reported to the study site IRB within two business days 
and to the study sponsor within 72 hours.
Sample size
This study will recruit 25 young adults 18–25 years of 
age. This number was necessary to detect moderate with-
in-subjects effects (ie, f=0.35) with power >0.80 between 
conditions for the primary outcome measures, assuming 
a moderate correlation between measures (r>0.50).
Quantitative analyses
Following data cleaning and preparation, linear mixed-ef-
fect models including two within-subject factors (condi-
tion and time) will be used to assess the condition effect 
on the physiological (saliva nicotine), behavioural (cross-
over point, breakpoint, elasticity, intensity, Omax, Pmax 
and cross-price elasticity) and subjective effect outcomes. 
Mixed-effect logistic or linear models will be fit to the 
data depending on the distribution of the error term. 
All models use an independent covariance matrix and 
estimate robust standard errors. Predicted probabilities 
(logistic mixed-effects models) and predicted values 
(linear mixed models) for condition effects will be esti-
mated with bootstrapped CI. We will also test for jointly 
significant condition effects across models of physiolog-
ical, behavioural choice task and subjective measures 
of abuse liability. Secondary outcomes (CO, HR, BP, 
average puff volume, puff duration, flow rate and total 
puff volume) will be analysed similarly. All analyses will be 
performed in Stata V.15.
EthICAl ConsIdErAtIons And dIssEMInAtIon
Ethics approval was granted. All personnel were trained 
on study procedures, conducting research with human 
Figure 1 Session timeline in minutes. *, 10 puffs of session 
product administered; B, behavioural measures administered; 
CO, expired air CO measured; End, physiological monitoring 
ends; Phys, physiological monitoring begins and mouth rinse; 
S, subjective measures administered; Sal, saliva collection.
Library. Protected by copyright.
 o
n
 O
ctober 15, 2019 at VA Com
m
 Univ Tom
pkins M
CCaw
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-023850 on 10 October 2018. Downloaded from 
7Wall CS, et al. BMJ Open 2018;8:e023850. doi:10.1136/bmjopen-2018-023850
Open access
subjects and data safety and monitoring protocols. This 
study was funded by the National Institute on Drug Abuse 
of the National Institutes of Health and the Food and Drug 
Administration (1R03DA043005) and was registered at 
ClinicalTrials. gov with protocol number NCT0237051.
Dissemination channels for study findings will include 
publishing in the scientific literature, presentations at 
scientific meetings and a policy brief to communicate the 
implications of the study’s findings to policymakers and 
communities.
study stAtus
Study recruitment began in March 2017. The target sample 
size is n=25. As of the time of this submission (April 2018), 
30 participants have been consented, 12 failed in-person 
eligibility screening, three have withdrawn, one is currently 
enrolled and 14 have completed the study. Recruitment is 
expected to be completed by May 2018.
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